Abstract
AbstractThiazolidinediones are a new class of oral hypoglycaemic agents, which have been reviewed by the National Institute for Clinical Excellence (NICE) and guidelines published. There is ambiguity in the NICE guidelines regarding the use of the triple combination of sulphonylurea, metformin and thiazolidinedione to treat type 2 diabetes. However, in our retrospective audit we found that triple therapy was used in 52% of patients treated with thiazolidinediones. When we analysed the effect of triple therapy we found that it significantly (p<0.05) reduced HbA1c from 9.6% (±1.5%) to 8.4% (±1.1%). Further prospective studies will be needed to confirm this. Copyright © 2003 John Wiley & Sons, Ltd. Copyright © 2003 John Wiley & Sons, Ltd.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
